https://www.maio-journal.com/index.php/MAIO <p>Modeling and Artificial Intelligence in Ophthalmology (MAIO) provides a forum for interdisciplinary approaches integrating techniques from mathematics, computer science, engineering and experimental and clinical sciences to address open problems in ophthalmology.</p> <p>MAIO uses the Continuous Article Publication (CAP) model. Articles are published as soon as they are ready. In general within 4 weeks after acceptance of your paper</p> <p>Read more about MAIO's <a title="JMO Focus &amp; Scope" href="https://www.maio-journal.com/index.php/MAIO/about/#focusAndScope" target="_blank" rel="noopener">focus and scope</a>.<br /><a href="https://www.maio-journal.com/index.php/JMO/issue/archive">See all issues here</a></p> <p style="text-align: center;"> </p> Kugler Publications en-US Modeling and Artificial Intelligence in Ophthalmology 2772-9591 <p>Authors who publish with this journal agree to the following terms:</p><ol type="a"><li><p>Authors retain copyright and grant the journal right of first publication, with the work twelve (12) months after publication simultaneously licensed under a <a href="http://creativecommons.org/licenses/by/3.0/" target="_new">Creative Commons Attribution License</a> that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.</p></li><li>After 12 months from the date of publication, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li></ol> https://www.maio-journal.com/index.php/MAIO/article/view/122 <p><em>Purpose:</em> To report the clinical experiences of author AH, who calculated that modest stepwise lowering of arterial blood pressure can reverse (i) re-emergent diabetic retinopathy (DR) caused by antiplatelet and anticoagulant agents, even in the presence of continued use of the latter necessary agents, or (ii) DR induced by common or severe hypertension and so, (iii) simultaneously treat both of AH’s vascular and ocular medical conditions.</p> <p><em>Methods:</em> In instances of DR and visual impairment with evidence of exudate formation, blood pressure adjustments were applied, based on mathematical models of retinal exudate production developed by one of the authors (AH). Specifically, the model was used to calculate a critical arterial blood pressure below which retinal exudate formation should cease. Antihypertensive agents were then increased gradually until the desired lower target blood pressure was achieved and DR eliminated. Optical coherence tomography (OCT) was used to test for therapeutic effectiveness.</p> <p><em>Results:</em> In four different clinical situations, which included blood thinners or hypertension, control of retinal exudate formation and elimination of re-emergent DR was achieved solely by blood pressure lowering and confirmed (with OCT) by return, to normal, of retinal measurements and vision.</p> <p><em>Conclusion:</em> While the evidence presented here is derived from clinical examples in one person and not from a statistically justified large study, this approach to the control of retinal exudate formation offers very effective unintrusive management of a common vision-threatening aspect of DR. In particular, this approach avoids laser treatments and the challenging experience of commonly administered intraocular injections. Clinical and mathematical evidence is presented that treatment with abundant vitamin B1 (300 mg) and vitamin D results in partial cure of DR. A cure to DR has not been reported before.</p> <p><em>Future perspectives:</em> The reversal of DR and potentially age-related macular degeneration (ARMD), with safe and simple measures, is an incredibly worthy management goal for these two very common conditions. The possibility demands urgent evaluation with what should be zero- or low-risk clinical trials.</p> Arieh Helfgott John O. Willoughby Copyright (c) 2024 Arieh Helfgott, John O. Willoughby https://creativecommons.org/licenses/by-nc/4.0 2024-02-13 2024-02-13 6 1 1 63 10.35119/maio.v6i1.122